IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): A Study to Explore the Feasibility of using Combined Modalities to Test the Safety of CaridMEMS Device in PAH Patients

IGF::OT::IGF 血管干预/创新和治疗进展 (VITA)：一项探索使用组合方式测试 CaridMEMS 设备在 PAH 患者中安全性的可行性的研究

• 批准号: 8947688
• 负责人: RAYMOND Louis Benza
• 金额: $ 28.77万
• 依托单位: ALLEGHENY-SINGER RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-12-01 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8947688
• 关键词: Blood Vessels; Clinical; Clinical assessments; Computer software; Contracts; Development; Devices; Diagnostic; Disease; Disease Progression; Future; Goals; Imaging technology; Intervention; Learning; Medical; Modality; Monitor; National Heart, Lung, and Blood Institute; Patients; Pulmonary Hypertension; Risk; Staging; Support Contracts; Testing; Therapeutic; Vascular Diseases; hemodynamics; improved; innovation; novel; product development; prognostic; programs; pulmonary arterial hypertension; safety testing; tool

The Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program is a new translational initiative of the National Heart, Lung, and Blood Institute (NHLBI) that enables and accelerates the development of promising diagnostic and therapeutic modalities for unmet and underserved medical needs. The VITA Program provides contract support for early-stage translational development of product candidates in the fields of vascular disorders, thrombotic diseases, and pulmonary hypertension.

血管干预/创新和治疗进展（VITA）计划是国家心脏，肺和血液研究所（NHLBI）的一项新的翻译计划，可实现并加速有希望的诊断和治疗方式，以实现未满足和不受欢迎的医疗需求。 VITA计划为在血管疾病，血小板疾病和肺动脉高压领域的候选产品的早期翻译发展提供了合同支持。